Gencurix Inc. (229000.KQ)
KRW 1446.0
(-0.69%)
KRW 1446.0
(-0.69%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1629.25 KRW | 50.79% |
| 2022 | -3310.49 KRW | 30.11% |
| 2021 | -4736.89 KRW | -194.98% |
| 2020 | 4987.08 KRW | 429.9% |
| 2019 | -1511.71 KRW | -49.57% |
| 2018 | -1010.72 KRW | 22.11% |
| 2017 | -1297.57 KRW | 30.96% |
| 2016 | -1879.49 KRW | -107.65% |
| 2015 | -905.14 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -227.10 KRW | 9.24% |
| 2024 Q2 | -280.68 KRW | -23.73% |
| 2023 Q1 | -920.17 KRW | -93.17% |
| 2023 Q3 | -208.21 KRW | 58.83% |
| 2023 Q4 | -250.23 KRW | -20.18% |
| 2023 Q2 | -505.79 KRW | 45.03% |
| 2023 FY | - KRW | 50.79% |
| 2022 Q2 | -1348.14 KRW | -53.02% |
| 2022 FY | - KRW | 30.11% |
| 2022 Q4 | -476.36 KRW | 22.31% |
| 2022 Q3 | -613.16 KRW | 54.52% |
| 2022 Q1 | -881.05 KRW | 33.74% |
| 2021 FY | - KRW | -194.98% |
| 2021 Q2 | 952.95 KRW | 129.14% |
| 2021 Q3 | -1103.00 KRW | -215.75% |
| 2021 Q4 | -1329.74 KRW | -20.56% |
| 2021 Q1 | -3270.77 KRW | -170.67% |
| 2020 Q1 | -538.02 KRW | 39.89% |
| 2020 FY | - KRW | 429.9% |
| 2020 Q4 | 4627.92 KRW | 3026.97% |
| 2020 Q3 | 148.00 KRW | 272.09% |
| 2020 Q2 | -86.00 KRW | 84.02% |
| 2019 FY | - KRW | -49.57% |
| 2019 Q4 | -895.00 KRW | -64.83% |
| 2019 Q3 | -543.00 KRW | 0.0% |
| 2018 FY | - KRW | 22.11% |
| 2017 FY | - KRW | 30.96% |
| 2016 FY | - KRW | -107.65% |
| 2015 FY | - KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 9148.00 KRW | 117.81% |
| InBody Co.,Ltd | 2819.01 KRW | 157.795% |
| Curexo Inc. | -120.00 KRW | -1257.708% |
| Seegene, Inc. | 14.19 KRW | 11581.677% |
| i-SENS, Inc. | 134.89 KRW | 1307.836% |
| Ray Co., Ltd. | -140.25 KRW | -1061.676% |
| Sugentech Inc. | -1090.00 KRW | -49.472% |
| L&C Bio Co., Ltd | 2096.33 KRW | 177.719% |